TY - JOUR T1 - <em>ACE2</em> variants underlie interindividual variability and susceptibility to COVID-19 in Italian population JF - medRxiv DO - 10.1101/2020.04.03.20047977 SP - 2020.04.03.20047977 AU - Benetti Elisa AU - Tita Rossella AU - Spiga Ottavia AU - Ciolfi Andrea AU - Birolo Giovanni AU - Bruselles Alessandro AU - Doddato Gabriella AU - Giliberti Annarita AU - Marconi Caterina AU - Musacchia Francesco AU - Pippucci Tommaso AU - Torella Annalaura AU - Trezza Alfonso AU - Valentino Floriana AU - Baldassarri Margherita AU - Brusco Alfredo AU - Asselta Rosanna AU - Bruttini Mirella AU - Furini Simone AU - Seri Marco AU - Nigro Vincenzo AU - Matullo Giuseppe AU - Tartaglia Marco AU - Mari Francesca AU - Renieri Alessandra AU - Pinto Anna Maria Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/04/06/2020.04.03.20047977.abstract N2 - In December 2019, an initial cluster of unexpected interstitial bilateral pneumonia emerged in Wuhan, Hubei province. A human-to-human transmission was immediately assumed and a previously unrecognized entity, termed coronavirus disease 19 (COVID- 19) due to a novel coronavirus (2019-nCov) was suddenly described. The infection has rapidly spread out all over the world and Italy has been the first European Country experiencing the endemic wave with unexpected clinical severity in comparison with Asian countries.It has recently been shown that 2019-nCov utilizes host receptors namely angiotensin converting enzyme 2 (ACE2) as host receptor and host proteases for cell surface binding and internalization. Thus, a predisposing genetic background can give reason for interindividual disease susceptibility and/or severity. Taking advantage of the Network of Italian Genomes (NIG), here we mined around 7000 exomes from 5 different Centers looking for ACE2 variants. A number of variants with a potential impact on protein stability were identified. Among these, three missense changes, p.Asn720Asp, p.Lys26Arg, p.Gly211Arg (MAF 0.002 to 0.015), which have never been reported in the Eastern Asia population, were predicted to interfere with protein u and stabilization. Rare truncating variants likely interfering with the internalization process and one missense variant, p.Trp69Cys, predicted to interfere with 2019-nCov spike protein binding were also observed.These findings suggest that a predisposing genetic background may contribute to the observed inter-individual clinical variability associated with COVID-19. They allow an evidence-based risk assessment opening up the way to personalized preventive measures and therapeutic options.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was, in part, supported by: Telethon Network of Genetic Biobanks (project no. GTB12001), funded by Telethon Italy; Fondazione Bambino Gesú (Vite Coraggiose to M.T.); Mount Sinai, NY (USA) in the context of the international project ASC (Autism sequencing consortium); SOLVE-RD and MIUR project “Dipartimenti di Eccellenza 2018 — 2022” (n° D15D18000410001) to the Department of Medical Sciences, University of Torino (G.M., A.B.). We thank the CINECA consortium for providing computational resources. Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesI declare availability to the data referred to in the manuscript and note links below. ER -